{"id":898708,"date":"2025-10-22T08:15:44","date_gmt":"2025-10-22T12:15:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/"},"modified":"2025-10-22T08:15:44","modified_gmt":"2025-10-22T12:15:44","slug":"charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/","title":{"rendered":"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development<\/b><\/p>\n<p>WILMINGTON, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCharles River Laboratories International, Inc. (NYSE: CRL) and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies.<\/p>\n<p>\nThis agreement leverages an integrated approach to streamline discovery and characterization\u2014bringing promising ADC candidates to the clinic faster and more efficiently. This end-to-end approach\u2014spanning antibody discovery, conjugation, <i>in vitro<\/i> profiling, and preclinical studies\u2014will be fully integrated and managed jointly by Charles River and the Crick to minimize timelines and maximize efficiency.<\/p>\n<p>\n\u201cThis integrated ADC development agreement represents a powerful synergy between cutting-edge antibody discovery and rigorous safety profiling,\u201d said Justin Bryans, PhD, Chief Scientific Officer, Charles River. \u201cTogether, we\u2019re enabling the development of smarter, safer therapeutics that are more likely to succeed in the clinic\u2014ultimately supporting the mission of delivering life-changing therapies to patients.\u201d<\/p>\n<p>\nThis collaboration will feature antibody generation leveraging phage display libraries, ensuring high-affinity, target-specific antibodies as the foundation for ADC development. It will also utilize Charles River\u2019s advanced Retrogenix\u2122 platform, an <i>in<\/i><i>vitro<\/i> profiling technology designed to evaluate off-target interactions and enhance safety and therapeutic index early in the development process.<\/p>\n<p>\nDavid Allen, Director of Translation at the Crick, added, \u201cThis collaboration marks a powerful convergence of innovation and execution. Working together will allow us to translate our research discoveries into new treatments at a scale and speed that simply wouldn\u2019t be possible alone.\u201d<\/p>\n<p><b>About Charles River<br \/>\n<br \/><\/b>Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.criver.com&amp;esheet=54340621&amp;newsitemid=20251022172793&amp;lan=en-US&amp;anchor=www.criver.com&amp;index=1&amp;md5=5b9dab016e9927728d8e4e9ee2af1b7d\">www.criver.com<\/a>.<\/p>\n<p><b>About The Francis Crick Institute<br \/>\n<br \/><\/b>The Francis Crick Institute is a biomedical discovery institute with the mission of understanding the fundamental biology underlying health and disease. Its work helps improve our understanding of why disease develops which promotes discoveries into new ways to prevent, diagnose and treat disease.<\/p>\n<p>\nAn independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King&#8217;s College London.<\/p>\n<p>\nThe Crick was formed in 2015, and in 2016 it moved into a brand new state-of-the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under a single roof in Europe. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4485755-1%26h%3D1632687320%26u%3Dhttp%253A%252F%252Fcrick.ac.uk%252F%26a%3Dhttp%253A%252F%252Fcrick.ac.uk%252F&amp;esheet=54340621&amp;newsitemid=20251022172793&amp;lan=en-US&amp;anchor=http%3A%2F%2Fcrick.ac.uk%2F&amp;index=2&amp;md5=d1cfd4efb50bc3334b902361ec71ccb8\">http:\/\/crick.ac.uk\/<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251022172793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251022172793\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251022172793\/en\/<\/a><\/span><\/p>\n<p><b>Charles River Investor Contact:<br \/>\n<\/b><br \/>Todd Spencer<br \/>\n<br \/>Corporate Vice President,<br \/>\n<br \/>Investor Relations<br \/>\n<br \/>781.222.6455<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:todd.spencer@crl.com\">todd.spencer@crl.com<\/a><\/p>\n<p><b>Charles River Media Contact:<br \/>\n<\/b><br \/>Amy Cianciaruso<br \/>\n<br \/>Corporate Senior Vice President,<br \/>\n<br \/>Chief Communications Officer<br \/>\n<br \/>781.222.6168<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:amy.cianciaruso@crl.com\">amy.cianciaruso@crl.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Medical Devices Health Research Pharmaceutical Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251022172793\/en\/836653\/3\/charles_river_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development WILMINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories International, Inc. (NYSE: CRL) and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies. This agreement leverages an integrated approach to streamline discovery and characterization\u2014bringing promising ADC candidates to the clinic faster and more efficiently. This end-to-end approach\u2014spanning antibody discovery, conjugation, in vitro profiling, and preclinical studies\u2014will be fully integrated and managed jointly by Charles River and the Crick to minimize timelines and maximize efficiency. \u201cThis integrated ADC development agreement represents a powerful synergy between cutting-edge antibody discovery and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-898708","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development WILMINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories International, Inc. (NYSE: CRL) and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies. This agreement leverages an integrated approach to streamline discovery and characterization\u2014bringing promising ADC candidates to the clinic faster and more efficiently. This end-to-end approach\u2014spanning antibody discovery, conjugation, in vitro profiling, and preclinical studies\u2014will be fully integrated and managed jointly by Charles River and the Crick to minimize timelines and maximize efficiency. \u201cThis integrated ADC development agreement represents a powerful synergy between cutting-edge antibody discovery and &hellip; Continue reading &quot;Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T12:15:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251022172793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development\",\"datePublished\":\"2025-10-22T12:15:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/\"},\"wordCount\":543,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251022172793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/\",\"name\":\"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251022172793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-10-22T12:15:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251022172793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251022172793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/","og_locale":"en_US","og_type":"article","og_title":"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development - Market Newsdesk","og_description":"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development WILMINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories International, Inc. (NYSE: CRL) and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies. This agreement leverages an integrated approach to streamline discovery and characterization\u2014bringing promising ADC candidates to the clinic faster and more efficiently. This end-to-end approach\u2014spanning antibody discovery, conjugation, in vitro profiling, and preclinical studies\u2014will be fully integrated and managed jointly by Charles River and the Crick to minimize timelines and maximize efficiency. \u201cThis integrated ADC development agreement represents a powerful synergy between cutting-edge antibody discovery and &hellip; Continue reading \"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-22T12:15:44+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251022172793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development","datePublished":"2025-10-22T12:15:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/"},"wordCount":543,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251022172793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/","name":"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251022172793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-10-22T12:15:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251022172793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251022172793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-the-francis-crick-institute-combine-expertise-in-antibody-drug-conjugate-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=898708"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898708\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=898708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=898708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=898708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}